OBJECTIVES: Heat shock protein 90 regulates multiple signaling proteins involved in key pathways of pancreatic cancer pathogenesis. Ganetespib binds to heat shock protein 90 and interferes with its binding to client proteins thus leading to inactivation and degradation of the signaling proteins that promote cancer progression. This phase II study was designed to evaluate the efficacy of ganetespib in patients with refractory metastatic pancreatic cancer (rMPC). METHODS: Patients with rMPC received 175 mg/m ganetespib intravenously once weekly for 3 weeks in 4-week cycles. Primary endpoint was disease control rate at 8 weeks, with a goal of 70%. Secondary endpoints were progression-free survival, overall survival, and safety. Simon's 2-stage design was used to assess futility and efficacy. Ganetespib was considered inactive if ≤8 patients among the first 15 treated had disease control after 8 weeks of treatment. RESULTS: Fourteen patients were treated on study. Grade 3 treatment-related toxicities were diarrhea, abdominal pain, fatigue, nausea, vomiting, and hyponatremia. Disease control rate at 8 weeks was 28.6%, and median progression-free survival and overall survival were 1.58 months and 4.57 months, respectively. Early stopping rules for lack of clinical efficacy led to study closure. CONCLUSIONS: Single-agent ganetespib was tolerable with only modest disease control in rMPC. This disease is resistant to chemotherapy, and given the emerging data in lung and rectal cancers, as well as in pancreatic cancer cell lines, suggesting improved activity of ganetespib in combination with cytotoxic agents, studies combining this agent with chemotherapy in rMPC are more likely to yield success.
OBJECTIVES:Heat shock protein 90 regulates multiple signaling proteins involved in key pathways of pancreatic cancer pathogenesis. Ganetespib binds to heat shock protein 90 and interferes with its binding to client proteins thus leading to inactivation and degradation of the signaling proteins that promote cancer progression. This phase II study was designed to evaluate the efficacy of ganetespib in patients with refractory metastatic pancreatic cancer (rMPC). METHODS:Patients with rMPC received 175 mg/m ganetespib intravenously once weekly for 3 weeks in 4-week cycles. Primary endpoint was disease control rate at 8 weeks, with a goal of 70%. Secondary endpoints were progression-free survival, overall survival, and safety. Simon's 2-stage design was used to assess futility and efficacy. Ganetespib was considered inactive if ≤8 patients among the first 15 treated had disease control after 8 weeks of treatment. RESULTS: Fourteen patients were treated on study. Grade 3 treatment-related toxicities were diarrhea, abdominal pain, fatigue, nausea, vomiting, and hyponatremia. Disease control rate at 8 weeks was 28.6%, and median progression-free survival and overall survival were 1.58 months and 4.57 months, respectively. Early stopping rules for lack of clinical efficacy led to study closure. CONCLUSIONS: Single-agent ganetespib was tolerable with only modest disease control in rMPC. This disease is resistant to chemotherapy, and given the emerging data in lung and rectal cancers, as well as in pancreatic cancer cell lines, suggesting improved activity of ganetespib in combination with cytotoxic agents, studies combining this agent with chemotherapy in rMPC are more likely to yield success.
Authors: Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux Journal: N Engl J Med Date: 2011-05-12 Impact factor: 91.245
Authors: Takeshi Shimamura; Samanthi A Perera; Kevin P Foley; Jim Sang; Scott J Rodig; Takayo Inoue; Liang Chen; Danan Li; Julian Carretero; Yu-Chen Li; Papiya Sinha; Christopher D Carey; Christa L Borgman; John-Paul Jimenez; Matthew Meyerson; Weiwen Ying; James Barsoum; Kwok-Kin Wong; Geoffrey I Shapiro Journal: Clin Cancer Res Date: 2012-07-17 Impact factor: 12.531
Authors: Dongweon Song; Raghothama Chaerkady; Aik Choon Tan; Elena García-García; Anuradha Nalli; Ana Suárez-Gauthier; Fernando López-Ríos; Xian Feng Zhang; Anna Solomon; Jeffrey Tong; Margaret Read; Christian Fritz; Antonio Jimeno; Akhilesh Pandey; Manuel Hidalgo Journal: Mol Cancer Ther Date: 2008-10 Impact factor: 6.261
Authors: Mark A Socinski; Jonathan Goldman; Iman El-Hariry; Marianna Koczywas; Vojo Vukovic; Leora Horn; Eugene Paschold; Ravi Salgia; Howard West; Lecia V Sequist; Philip Bonomi; Julie Brahmer; Lin-Chi Chen; Alan Sandler; Chandra P Belani; Timothy Webb; Harry Harper; Mark Huberman; Suresh Ramalingam; Kwok-Kin Wong; Florentina Teofilovici; Wei Guo; Geoffrey I Shapiro Journal: Clin Cancer Res Date: 2013-04-03 Impact factor: 12.531
Authors: Lipika Goyal; Raymond C Wadlow; Lawrence S Blaszkowsky; Brian M Wolpin; Thomas A Abrams; Nadine Jackson McCleary; Susan Sheehan; Eamala Sundaram; Michael D Karol; John Chen; Andrew X Zhu Journal: Invest New Drugs Date: 2014-09-24 Impact factor: 3.850
Authors: Timothy J Haggerty; Ian S Dunn; Lenora B Rose; Estelle E Newton; Franco Pandolfi; James T Kurnick Journal: PLoS One Date: 2014-12-12 Impact factor: 3.240